Status: Recruiting
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.
Participants needed: 162
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.Updated: Mar 4, 2026Locations: 3
Eligibility criteria
Patients able to give written informed consent; [+7]
Patients who have had previous treatment with any anti-DLL3 antibody; [+8]